Evaluation methods for anti-infective drugs, vaccines, etc. using immortalized monocytes and induced cells
By introducing specific genes into monocytes or dendritic cells and achieving immortalization, the problem of cell supply and virus isolation in infectious microbial research is solved, the efficiency of infection evaluation and vaccine development is improved, and efficient viral mutation is achieved Obtain the plant.
Patent Information
- Application Number
- CN201980056313.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-27
- Filing Date
- 2019-08-26
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2039-08-26
AI Technical Summary
The prior art has poor stability, reproducibility and operability in the study of infectious microorganisms mediated by monocytes or dendritic cells, making it difficult to continuously proliferate and provide a sufficient number of cells, resulting in a low success rate of infection evaluation and virus isolation. Moreover, the virus mutant strain has been acquired for a long time during vaccine development.
By introducing BMI1, EZH2, MDM2, HIF1A, BCL2 and LYL1 genes equal to monocytes or dendritic cells, their proliferation and infection are achieved, and the immortalization method is used to stably obtain monocytes or dendritic cells with high CD4 expression, improving Virus isolation success rate and mutant strain acquisition speed.
It has achieved efficient culture of infectious microorganisms mediated by monocytes or dendritic cells and rapid acquisition of viral mutants, improved the reproducibility of infection evaluation and vaccine development efficiency, and solved the problems of cell supply and virus isolation.
Smart Images

Figure HDA0002951742180000011 
Figure HDA0002951742180000021 
Figure HDA0002951742180000031
Abstract
Description
Technical Field
[0001] The present invention relates to an in vitro culture method of infectious microorganisms mediated by monocytes or dendritic cells or a method for evaluating therapeutic drugs for infectious diseases caused by the microorganisms. Background Art
[0002] In infectious disease research, when target pathogens proliferate through monocytes or dendritic cells, studies are conducted using established cell lines. For example, dengue virus is a virus that causes human infection and has been studied for many years. Based on experience, studies are conducted using cell lines such as the K562 cell line derived from human chronic myeloid leukemia, the Vero cell line derived from the kidney epithelial cells of African macaques, and the BHK cell line derived from the kidney of Syrian hamsters. However, although evaluations using these cell lines have the advantage of being easy to conduct, there is a problem that they may not necessarily reflect infection and proliferation in the human body.
[0003] The use of human-derived monocytes and dendritic cells enables analysis of mechanisms and antigens that are closer to organisms, so it is expected that new drugs and vaccines will be developed based on this. In theory, infection evaluation can be performed using human-derived leukocyte-like cells, and cells separated from tissues removed from individuals can also be used for infection evaluation. For example, it is reported that hematopoietic stem cells derived from umbilical cord blood, bone marrow, and peripheral blood can be differentiated into blood cells in vitro, and even differentiated into monocytes and induced cells. In addition, there are also reports that methods for preparing monocytes and further differentiated dendritic cells by differentiation induction from pluripotent stem cells such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells) (Patent Document 1, Non-Patent Documents 1 to 9). However, monocytes and dendritic cells are difficult to proliferate continuously in vitro, so when using cells from resection sources for cell preparation, they need to be extracted and separated from individuals, which has the problem of complicated operation and high cost. In addition, these methods have the problem of time-consuming differentiation induction, small supply of monocytes and differentiated dendritic cells, and difficulty in continuously providing the amount required for research. In addition, there is a problem that the individual from which the cells are derived and the conditions for preparing the cells may differ each time, and therefore, there is a problem that reproducibility evaluation is difficult.
[0004] Thus, cells that fully reflect the infection and proliferation status in the human body with good reproducibility and can evaluate monocyte- or dendritic cell-mediated infectious microorganisms have not previously existed.
[0005] Due to such experimental limitations, although it has been clarified that infectious microorganisms mediated by monocytes or dendritic cells are mediated by monocytes and dendritic cells, all details about conditions suitable for virus proliferation have not been clarified. Therefore, in experiments using cells removed from individuals, there is also a problem that the study of infectious microorganisms mediated by monocytes or dendritic cells that are the subject of research is not necessarily conducted under suitable conditions.
[0006] On the other hand, since a large number of antigen-presenting cells need to be prepared for cell therapy in immunotherapy for cancer and the like, research has been conducted on antigen-presenting cells such as monocytes, macrophages, and dendritic cells that can proliferate. It has been reported that myeloid cell lines (iPS-ML) and monocyte cell lines (CD14-ML) with self-proliferation ability were produced by gene introduction into myeloid cells (iPS-MC) induced by differentiation from iPS cells and monocytes derived from peripheral blood (Patent Documents 2 and 3).
[0007] It is also disclosed that, as a dengue virus infection model, monocyte-derived dendritic cells are limited due to their quality, proliferation, and donor-dependence, and the dendritic cells (iPS-ML-DC) derived from the above-mentioned iPS-ML are infected with dengue virus to activate HLA (human leukocyte antigen)-matched T cells (non-patent document 10). However, when using iPS cells, there are many problems such as canceration due to the residue of iPS cells and difficulty in inducing myeloid cells from iPS cells to differentiate stably and highly reliably, and the need to reliably isolate only myeloid cells from the induced cell population. In addition, it is known that CD4+ monocytes have excellent ability as antigen presenting cells (non-patent document 11), while iPS-derived myeloid cells (iPS-ML) have low CD4 expression (non-patent document 12).
[0008] In addition, virus isolation from infected patients is an important operation for confirming infection and for inspection and research. Virus isolation is carried out by collecting blood from infected patients and performing operations using cultured cells. For example, in the case of dengue virus, serum samples within 5 to 6 days after onset and C6 / 36 cells, which are cultured cell lines for Aedes albopictus, are generally used for the operation (Non-patent Document 13). However, the virus concentration in the serum sample and the time from sample collection to the start of culture affect the efficiency of virus isolation, and there is a problem that virus isolation may not be successful. For example, it is known that in the case of dengue virus, the concentration of the virus in the serum sample decreases due to the patient's recovery, and the number of surviving viruses after blood collection continues to decrease. Therefore, it is known that the success rate of virus isolation is about 60%, and the ratio will be lower after the 5th day after the onset of the disease, when the amount of virus is believed to be reduced (Non-patent Document 14).
[0009] In addition, the development of vaccines requires the ability to cultivate cultured cells that can mutate the virus. In particular, the development of attenuated vaccines uses cells of heterologous cultures and the like to be repeatedly passaged to obtain attenuated virus variants for use as vaccines. However, the frequency of viral mutation is very low, requiring a long research time, i.e., cultivation time. For example, it has been reported that, when the rotavirus vaccine (RV1) is an attenuated vaccine, after the human virus is passaged 33 times using African green monkey kidney cells, the strain screened after 3 limiting dilutions is further passaged 7 times using Vero cells to obtain (non-patent literature 15). In this way, it is known that attenuated variants cannot be obtained without multiple cultivations.
[0010] Prior art literature
[0011] Patent Literature
[0012] Patent Document 1: WO2008 / 056734
[0013] Patent Document 2: WO2012 / 043651
[0014] Patent Document 3: Japanese Patent Application Laid-Open No. 2017-131136
[0015] Non-patent literature
[0016] Non-patent document 1: Fairchild PJ et al., Curr Biol. (2000) 10: 1515-1518.
[0017] Non-patent document 2: Lindmark H et al., Exp Cell Res (2004) 300: 335-344.
[0018] Non-patent document 3: Zhan X et al., Lancet (2004) 364: 163-171.
[0019] Non-patent document 4: SluKvin II et al., J Immunol (2006) 176: 2924-2932.
[0020] Non-patent document 5: Odegaard JI et al., J Leukoc Biol (2007) 81: 711-719.
[0021] Non-patent document 6: Su Z et al., Clin Cancer Res (2008) 14: 6207-6217.
[0022] Non-patent document 7: Tseng SY et al., Regen Med (2009) 4: 513-526.
[0023] Non-patent document 8: Senju S et al., Stem cells (2007) 25: 2720-2729.
[0024] Non-patent literature 9: Choi KD et al., J Clin Invest (2009) 119: 2818-2829.
[0025] Non-patent literature 10: Dao Huy Manhra et al., J Gen Virol. (2018) doi: 10.1099 / jgv.0.001119.
[0026] Non-patent literature 11: G. Szabo et al., J. Leukoc. Biol. (1990); 47(2): 111-20.
[0027] Non-patent literature 12: Chihiro Koba et al., PLoS One. 2013; 8(6): e67567.
[0028] Non-patent document 13: Kanoka, "Clinical Examination Frontier" (Modern Media) Vol. 61 No. 9, 2015 "Clinical Examination Frontier" 265.
[0029] Non-patent document 14: Richiard G. Jarman et al., Am J Trop Med Hyg. 2011; 84(2): 218-223.
[0030] Non-patent document 15: Rotavirus Fact Sheet (September 28, 2012) National Institute of Infectious Diseases Summary of the invention
[0031] That is, the subject of the present invention is to find a method with better stability, reproducibility, economy and ease of operation in the study of infectious microorganisms mediated by monocytes or dendritic cells. In addition, the object of the present invention is to provide a method for obtaining variants of infectious microorganisms mediated by monocytes or dendritic cells by short-term culture.
[0032] The inventor of the present invention has carried out research on dengue virus infection in order to explore a method for providing a monocyte or dendritic cell suitable for infectious disease research, and has conducted research on monocytes and dendritic cells prepared and manufactured by various methods. As a result, it was found that dengue virus can efficiently infect and proliferate in human monocytes that can proliferate by introducing genes into CD14 positive cells derived from human umbilical cord blood, ES cells, bone marrow cells or peripheral blood cells, and cells (such as dendritic cells) with phagocytic ability obtained by differentiation induction of the monocytes, thereby completing the present invention. In particular, the proliferation rate of viruses infected with these cells is fast, and more progeny viruses and virus-like particles are produced. Thus, the inventor of the present invention provides a new method for research and development for the evaluation method of pharmaceuticals such as compounds, vaccines, etc. for treating infectious microbial infectious diseases mediated by monocytes or dendritic cells. In addition, by making the proliferation of infectious microorganisms mediated by monocytes or dendritic cells possible, it was successfully found that it can be used for the manufacture of vaccines and the construction, development, and manufacture of variants.
[0033] In addition, the present invention solves these problems that exist by using iPS cells, especially by immortalizing monocytes for use. That is, by adopting a method for immortalizing monocytes, a population of only monocytes can be obtained stably and easily. In addition, the cells obtained by immortalizing monocytes express CD4, and have a stronger antigen presentation ability than iPS-derived dendritic cells, and are considered to be suitable cells for vaccine research. Therefore, the present invention provides a monocyte or dendritic cell-mediated infectious microorganism infection model with excellent CD4 expression.
[0034] In addition, due to the influence of the virus concentration in the sample, cell culture has always been difficult to separate viruses, and the present invention solves this problem. According to the discovery of the inventor of the present invention, by using the immortalization of CD14 positive cells derived from iPS cells, human umbilical cord blood, ES cells, bone marrow cells or peripheral blood to obtain human monocytes that can proliferate, and cells with phagocytic ability (such as dendritic cells) obtained by inducing differentiation of the monocytes, even if the amount of virus is scarce, it can be fully proliferated in the cell. As a result, the present invention successfully provides a separation evaluation system that improves the success rate of virus separation. Therefore, in one embodiment, the present invention provides an excellent cell for virus separation.
[0035] In addition, the present invention solves the problem of taking a long time to obtain virus variants of attenuated viruses during vaccine development. That is, through the present invention, for human monocytes that can proliferate obtained by immortalizing CD14 positive cells derived from iPS cells, human umbilical cord blood, ES cells, or bone marrow cells or peripheral blood, and cells with phagocytic ability (such as dendritic cells) obtained by inducing differentiation of the monocytes, even when infected with low-concentration viruses, it is not necessary to culture for a long time to obtain virus variants that form plaques of different forms. As a result, virus variants can be obtained in a short time, which are considered to be cells suitable for vaccine research. Therefore, the present invention provides cells that are beneficial to the production of variants in virus and vaccine research.
[0036] Specifically, the present invention relates to the following inventions.
[0037] (1) A method for maintaining and culturing infectious microorganisms mediated by monocytes or dendritic cells, comprising:
[0038] A step of infecting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated from the monocytes, with the infectious microorganisms; and
[0039] Steps for culturing infected cells.
[0040] (2) A method for maintaining and culturing infectious microorganisms mediated by monocytes or dendritic cells, comprising:
[0041] A step of introducing at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene into monocytes;
[0042] A step of inducing dendritic cells by differentiation from any of the above monocytes;
[0043] a step of infecting the obtained monocytes or dendritic cells with the above-mentioned infectious microorganisms; and
[0044] Steps for culturing infected cells.
[0045] (3) A method for identifying a therapeutic drug for infectious diseases mediated by monocytes or dendritic cells and containing infectious microorganisms, comprising:
[0046] A step of infecting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated from the monocytes, with the infectious microorganism in the presence of a test drug;
[0047] A step of determining the infection level of the infectious microorganism in the monocytes or dendritic cells;
[0048] The step of determining whether the drug under test has the above-mentioned infectious disease treatment effect according to the infection status of the above-mentioned infectious microorganisms determined,
[0049] Here, the measured infection level of the infectious microorganism is compared with the infection level of a control in which the cells are infected with the infectious microorganism in the absence of the test drug. If the former is lower, the test drug is judged to have the therapeutic effect on the infectious disease.
[0050] (4) A method for producing a variant strain of an infectious microorganism mediated by a monocyte or a dendritic cell, comprising:
[0051] A step of infecting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated and induced from the monocytes, with the infectious microorganisms described above;
[0052] A step of culturing the infected monocytes or the above-mentioned dendritic cells to proliferate the above-mentioned infectious microorganisms;
[0053] A step of isolating a mutant strain from the proliferated infectious microorganisms described above.
[0054] (5) A method for producing a monocyte- or dendritic cell-mediated infectious microorganism vaccine, comprising:
[0055] A step of infecting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated and induced from the monocytes, with the infectious microorganisms described above;
[0056] A step of culturing the infected monocytes or the above-mentioned dendritic cells to proliferate the above-mentioned infectious microorganisms;
[0057] A step of recovering the above-mentioned proliferated infectious microorganisms.
[0058] (6) The method according to item (5), further comprising the step of inactivating the recovered infectious microorganisms.
[0059] (7) A method for isolating infectious microorganisms from the blood of a patient suffering from an infectious disease mediated by monocytes or dendritic cells, comprising:
[0060] A step of contacting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated and induced from the monocytes, with blood from the patient;
[0061] Steps for culturing infected cells;
[0062] The step of identifying infectious microorganisms by detecting and / or identifying the microorganisms in cultured cells.
[0063] (8) The method according to any one of items (1) to (7), wherein the monocytes are cells obtained by differentiation induction of human pluripotent stem cells or human hematopoietic stem cells, or cells separated from human peripheral blood.
[0064] (9) The method according to item (8), wherein the human pluripotent stem cells are iPS cells.
[0065] (10) The method according to any one of items (1) to (7), further comprising the step of preparing monocytes by inducing differentiation of human pluripotent stem cells or human hematopoietic stem cells, or preparing monocytes by separation from human peripheral blood.
[0066] (11) The method according to item (10), wherein the human pluripotent stem cells are iPS cells.
[0067] (12) The method according to any one of items (1) to (11), wherein the infectious microorganism is dengue virus.
[0068] (13) The method according to any one of items (1) to (12), wherein at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene is BMI1 gene and EZH2 gene or LYL1 gene.
[0069] Effects of the Invention
[0070] Through the present invention, microorganisms that cause infectious diseases mediated by monocytes or dendritic cells can be studied and evaluated. For example, even for blood cell materials derived from human blood donations that are difficult to culture and evaluate for diseases that are difficult to study, the present invention can be used to culture and evaluate, and infectious disease research, anti-infective drugs, and vaccine development can be carried out. In addition, through the method of the present invention, in the development of therapeutic drugs for blood-related diseases, drug screening and evaluation with small errors can be carried out. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] Figure 1 The figure shows the results of analyzing the expression of surface markers CD11 and CD14 of the immortalized human monocytes produced by flow cytometry. Antibodies used: anti-CD11 antibody and anti-CD14 antibody reacting with FITC.
[0072] Figure 2 This is a photograph of dendritic cell-like cells induced by stimulating immortalized human monocytes with IL4 after May Giemsa staining.
[0073] Figure 3 This is the plate layout for the dengue virus infection experiment. The human monocytes or dendritic cells to be evaluated are added to the left half of the 96-well plate, and the control cells K562 cells are inoculated in the right half. Different dilutions of virus solution are added to each row of the wells (1-12). Different types of dengue virus (DENV-1: dengue virus type 1, DENV-2: dengue virus type 2, DENV-3: dengue virus type 3, DENV-4: dengue virus type 4) are added to each column of the wells (AH).
[0074] Figure 4 It means use Figure 3 The plate design of FIG. 1 shows a photograph of the results obtained by comparing the human dendritic-like cells prepared in Example 1 with the K562 cells of the positive subject. The dengue virus infection was visualized by staining after the dengue virus infection experiment.
[0075] Figure 5 yes Figure 4 (A) Photograph of the results using monocyte-like cells (ML: monocytic cells, K562: K562 cell line). From the left, wells A1, C1, E1, G1 (upper section), and Figure 4 (B) Photograph of the evaluation results using dendritic cells (DC: dendritic cells, K562: K562 cell line). Figure 4 A5, C5, E5, G5 holes (upper section), and Figure 4A7, C7, E7, and G7 holes (lower section) are enlarged photos of the A7, C7, E7, and G7 holes. Figure 4 Row A, column 1 of the board.
[0076] Figure 6 The graph shows the results of measuring the amount of virus released by monocyte-like cells (A) and dendritic cell-like cells (B). The vertical axis shows the amount of virus released in the culture supernatant (expressed as log10 plaque forming unit (PFU) / mL). The horizontal axis shows from the left: dengue virus type 1 (DENV-1) (D1), dengue virus type 2 (DENV-2) (D2), dengue virus type 3 (DENV-3) (D3), dengue virus type 4 (DENV-4) (D4).
[0077] Figure 7 This is a diagram showing the results of analyzing the cells after filtration using a flow cytometer in order to measure the physical purification and membrane strength of the immortalized human monocytes (peripheral blood-derived monocytes: CD14-ML, iPS cell-derived monocytes: iPS-ML). The group that was not purified by filtration (non-filtered group (Non filter)) and the group purified using a mesh filter with a mesh size of 12μm (12μm) were measured using a flow cytometer. The vertical axis shows the area of side scattered light (SSC-A), and the horizontal axis shows the detection results of forward scattered light (FSC-H). In order to visualize the degree of purification, the presence ratio of regions 1, 2, and others is shown for easy division. In order to ensure the reproducibility of the evaluation, management is achieved by keeping the cell number presence ratio in region 2 within a certain range.
[0078] Figure 8 Is to compare Figure 3 Well plate design for infection assessment when the virus dilution ratio is large and the virus concentration is low in the dengue virus infection experiment. Recorded based on experiments using dengue virus type 4 (DENV-4). 1*10^5 cells recorded in A to D were added to each well, and viruses were added according to the multiplicity of infection (MOI). For example, A1 (striped arrow) is infected with dengue virus type 4 (DENV-4) at a ratio of 1 peripheral blood-derived immortalized mononuclear cell (CD14-ML) to 0.39 (particles).
[0079] Fig. 9 This is a well plate design for dengue virus plaque experiment that further increases the virus dilution rate. Figure 8 After infection assessment, in order to visualize the amount of virus contained in the supernatant, the supernatant was inoculated onto Vero cells and cultured before immunostaining. Numbers correspond to Figure 8 For example, the upper left hole is Figure 8The supernatant of A1 was diluted 10-fold for inoculation.
[0080] Fig.10 This is a graph showing the results of a dengue virus infection experiment, showing that in the presence of extremely low virus concentrations, both peripheral blood-derived dendritic cells (CD14-DC: white arrows) and iPS cell-derived dendritic cells (iPS-DC: black arrows) proliferated and released the virus.
[0081] Fig.11 This is a graph showing the results of a dengue virus infection experiment. This is a graph showing infection with dengue virus type 1 while diluting the virus. The concentration of the virus in the light-colored spots (white arrows) varies with the concentration of the large spots (black arrows), indicating that there is a possibility of mutation between the two viruses. DETAILED DESCRIPTION
[0082] In one embodiment, the present invention relates to a method for maintaining and culturing infectious microorganisms mediated by monocytes or dendritic cells, comprising: allowing the above-mentioned infectious microorganisms to infect monocytes introduced with at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene, or dendritic cells induced by differentiation from the above-mentioned monocytes.
[0083] In another embodiment, the present invention relates to a method for maintaining a culture of monocytes or dendritic cells mediated infectious microorganisms, comprising:
[0084] A step of introducing at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene into monocytes;
[0085] A step of inducing differentiation of dendritic cells from any of the above monocytes; and
[0086] A step of infecting the obtained monocytes or dendritic cells with the above-mentioned infectious microorganisms.
[0087] <Monocyte- and dendritic-cell-mediated infectious microorganisms>
[0088] In this specification, "monocyte and dendritic cell-mediated infectious microorganisms" refers to viruses, bacteria, protozoa, etc. that include infection of monocytes or dendritic cells during their survival and proliferation. Such monocyte and dendritic cell-mediated infectious microorganisms include viruses of the Flaviviridae family that cause dengue fever, such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Zika virus, tick-borne encephalitis virus, etc.
[0089] <Method for preparing monocytes>
[0090] In the present invention, the monocytes used as raw materials can be obtained by methods of extraction from peripheral blood, methods of differentiation induction from pluripotent stem cells, methods of differentiation induction from other somatic cells such as fibroblasts, etc. When extracting monocytes from peripheral blood, the method of separating and preparing cells expressing CD14 molecules in human peripheral blood is well known. For example, it is diluted gently using physiological saline, phosphate buffered saline or Hanks buffer in an amount equal to that of human peripheral blood. The diluted blood is carefully layered on ficoll (registered trademark) (GE Healthcare) in a centrifuge tube and centrifuged at 15 to 30°C and 500 to 1000 × g for 20 minutes. The yellow plasma and the transparent white band-like layer in the middle of ficoll are recovered as peripheral blood mononuclear cells (PBMC) components composed of lymphocytes and monocytes. The recovered peripheral blood mononuclear cell component can also be used after further washing as needed. By further recovering cells expressing CD14 molecules from the recovered PBMC component, monocytes can be obtained. For example, PBMC is contacted with a solid phase bound to an anti-CD14 antibody, monocytes are bound to the solid phase, and unbound cells are washed and removed, thereby separating and recovering. For example, a method using magnetic beads as such a solid phase is known (Dynabeads (registered trademark) CD14 (ThermoFisher Scientific Inc.) etc.). In addition, monocytes can also be obtained by directly contacting peripheral blood with a solid phase bound to an anti-CD14 antibody without separating PBMC from peripheral blood.
[0091] When monocytes are differentiated from pluripotent cells, the method of inducing monocytes from pluripotent cells is well known. In this specification, "pluripotent stem cells" refers to cells with pluripotency and self-replication ability. In this specification, "pluripotency" is synonymous with multi-differentiation ability, and refers to the state of cells that can be differentiated into various tissues by differentiation. The multipotency in this specification includes the state that can be differentiated into all kinds of cells constituting an organism (differentiation totipotency), the state that can be differentiated into all kinds of cells except extraembryonic tissues (differentiation pluripotency), the state that can be differentiated into cells belonging to a part of the cell lineage (differentiation pluripotency), and the state that can be differentiated into a kind of cell (differentiation unipotency). Therefore, the "pluripotent stem cells" in this specification include stem cells, embryonic stem cells (ES), embryonic stem cells ("neES cells") derived from cloned embryos obtained by nuclear transplantation, germ stem cells ("GS cells"), embryonic germ cells ("EG cells"), induced pluripotent stem (iPS) cells and hematopoietic stem cells. Whether a cell is a pluripotent stem cell, for example, when the tested cell forms an embryoid body in an in vitro culture system, or differentiates into a desired cell after being cultured under differentiation induction conditions (differentiation treatment), the cell can be determined to be a pluripotent stem cell. The method of obtaining pluripotent stem cells is well known. For example, it has been reported that iPS cells are obtained by introducing three or more reprogramming genes (Oct3 / 4, Sox2, Klf4, c-Myc, L-Myc, Nanog, Lin28, Esrrb, Glisl, E-cadherin, shp53, UTX and Hlfoo, etc.) into somatic cells.
[0092] Differentiation induction from pluripotent stem cells to monocytes can be carried out, for example, by contacting pluripotent stem cells with macrophage colony stimulating factor (M-CSF) and interleukin 3 (IL-3) (see Fernando O.Martinez, Experimental Hematology (2008); 36; 1167-1175), or IFN-γ or PMA (Annabelle Grolleau et al., J Immunol 1999; 162: 3491-3497). The monocytes induced to differentiate can be purified by collecting only cells expressing CD14 as required by the above method.
[0093] Examples of methods for inducing differentiation of monocytes from other somatic cells such as fibroblasts include the method described in Takahiro Suzuku et al., “Reconstruction of Monocyte Transcriptional Regulatory Network Accompanies Monocytic Functions in Human Fibroblasts.” PLoS One (2012) doi: 10.1371 / journal.pone.0033474.
[0094] The obtained monocytes can be introduced into at least one gene selected from BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene, thereby increasing the proliferation capacity while maintaining the function of monocytes. Preferably, a combination of at least one gene selected from BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene and HIF1A gene and cMYC gene, or a combination of BMI1 gene and BCL2 gene or LYL1 gene and cMYC gene. The introduction of these genes into monocytes can refer to the records of WO2012 / 043651 and Japanese Patent Publication No. 2017-131136. For example, it can be introduced by infecting monocytes with lentiviral vectors carrying these genes.
[0095] <Method for preparing dendritic cells>
[0096] Induction of dendritic cells from monocytes can be carried out, for example, by culturing monocytes in the presence of 200 IU / ml of GM-CSF and 200 IU / ml of IL-4, according to already reported methods (Francoise Chapuis et al., Eur J Immunol. (1997) 27(2):431-41; Marc Dauer et al., J Immunil. (2003) 170(8):4069-4076; Figdor CG et al., Nat Med. (2004) 10(5):475-80; Helmut Jonuleit et al., Eur J Immunol. (1997) 27(12):3135-42).
[0097] <Monocyte- and dendritic cell-mediated infection and culture of infectious microorganisms>
[0098] Infectious microorganisms mediated by monocytes and dendritic cells can be infected by contacting monocytes or dendritic cells with a solution containing infectious microorganisms mediated by monocytes and dendritic cells. As a culture medium used for infection and / or post-infection culture, for example, IMDM solution, RPMI solution, α-MEM solution, MEM culture medium, DMEM solution can be cited. In addition, as additives, nucleic acid bases such as human or bovine plasma protein components, fetal bovine serum and human serum, sugars such as glucose, D-mannitol, amino acids, adenine, sodium hydrogen phosphate, α-tocopherol, linoleic acid, cholesterol, sodium selenite, human all-iron transferrin, human insulin, ethanolamine, 2-mercaptoethanol, EPO, TPO, sodium bicarbonate, methylcellulose, etc. can be included. In addition, as needed, antibiotics such as gentamicin, ampicillin, penicillin, streptomycin, inorganic salts, HEPES, phosphate buffer, acetate buffer, etc. can also be added. As a specific example, an α-MEM solution (10% fetal bovine serum) medium supplemented with non-essential amino acids can be used, or a medium supplemented with 10% fetal bovine serum, sodium bicarbonate, 100 units / ml penicillin, and 100 μg / mL streptomycin in RPMI1164 medium (SIGMA) containing hypoxanthine and HEPES (SIGMA) can be used. The culture time can be appropriately set according to the types of cells, microorganisms, and culture medium, for example, it can be 24 to 96 hours, 36 to 84 hours, or 72 hours. When culturing infected cells to obtain variants, the number of culture times can be a smaller number, for example, it can be 1 to 5 times, 1 to 4 times, 1 to 3 times, 1 to 2 times, or 1 time. Other culture conditions can be determined according to general human cell culture conditions, for example, at 37°C and 5% CO2.
[0099] <Therapeutic drug screening method>
[0100] In another embodiment, the present invention relates to a method for identifying a therapeutic drug for infectious diseases mediated by monocytes or dendritic cells and infectious microorganisms, comprising:
[0101] A step of infecting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated from the monocytes, with the infectious microorganism in the presence of a test drug;
[0102] A step of determining the infection level of the above infectious microorganisms in the above monocytes or dendritic cells;
[0103] The step of determining whether the drug under test has the above-mentioned infectious disease therapeutic effect according to the infection status of the above-mentioned infectious microorganisms determined.
[0104] The infection level of the infectious microorganism is measured and compared with the infection level of a control in which the cells are infected with the infectious microorganism in the absence of the test drug. If the former is lower, the test drug is determined to have the therapeutic effect on the infectious disease.
[0105] The infection level of the above-mentioned infectious microorganisms can be determined by measuring the infection titer of the above-mentioned microorganisms contained in the supernatant after the culture is completed using Cell-ELISA, immunostaining, plaque formation method or PCR method. Alternatively, it can be determined by fixing the infected cells after the culture is completed and performing immunostaining or Cell ELISA.
[0106] When the level of infection of monocytes or dendritic cells by infectious microorganisms mediated by monocytes and dendritic cells is detected by Cell-ELISA or immunostaining, the screening method of the present invention may include the step of fixing the infected monocytes or dendritic cells; and the step of contacting the fixed cells with antibodies specific to the infectious microorganisms mediated by the monocytes and dendritic cells. For example, in the present specification, the Cell-ELISA method may include: the step of contacting an antibody (primary antibody) that specifically binds to the microorganism with the fixed cells; the step of removing (washing) unbound antibodies; the step of contacting a labeled antibody (secondary antibody) that can bind to the primary antibody with the fixed cells after contact with the primary antibodies; the step of removing (washing) unbound antibodies; the step of measuring the labeling level (intensity, area, quantity, etc.) of the secondary antibody bound to the fixed cells; and the step of calculating the infection level of the microorganism that infects the cells based on the measured labeling level. Alternatively, in the present specification, the immunostaining method may include: a step of contacting a labeled antibody that can specifically bind to the microorganism with the immobilized cells; a step of removing (washing) unbound antibodies; a step of measuring the labeling level (intensity, area, quantity, etc.) of the above-mentioned antibody bound to the immobilized cells; and a step of calculating the infection level of the microorganism that infects the cells based on the measured labeling level. The label used for the labeled antibody may be a radioactive label, an enzyme label, a fluorescent label, a bioluminescent label, a chemiluminescent label, a metal, a near-infrared light label, or other detectable label.
[0107] When the level of infection of monocytes or dendritic cells by infectious microorganisms mediated by monocytes and dendritic cells is detected by plaque formation method, the method may include: mixing the culture supernatant of infected monocytes or dendritic cells or the liquid containing microorganisms recovered from cell fragments with a cell line known to be infected by the microorganism (e.g., K562 cell line, Vero cell line, or BHK cell line, etc.), adding the mixed cell / microorganism liquid to the culture medium, and culturing for 12 hours to 10 days; fixing the infected cells after culture; and contacting the immobilized cells with antibodies specific to the infectious microorganisms mediated by the monocytes and dendritic cells. The contact of the immobilized cells with the antibodies specific to the microorganisms can be specifically carried out by the above-mentioned Cell-ELISA method or immunostaining method.
[0108] When the level of infection of monocytes or dendritic cells by infectious microorganisms mediated by monocytes or dendritic cells is detected by PCR, for example, the detection can be performed by subjecting the culture supernatant of infected monocytes or dendritic cells or the liquid containing microorganisms recovered from cell fragments to real-time PCR as a sample.
[0109] The "infection level" is not particularly limited as long as it is a numerical value that can reflect the number of infectious microorganisms. For example, PFU, PFU / mL, infected area area, number of microorganisms (individuals) or microorganism concentration (individuals / mL) can be used. "The control infection level of the above-mentioned infectious microorganisms infecting the above-mentioned cells in the absence of the above-mentioned test drug" can be obtained by, at the same time as the presence of the test drug, as a control experiment, in the absence of the test drug, infecting the above-mentioned infectious microorganisms with monocytes introduced with at least one gene selected from the BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene, or dendritic cells induced by differentiation from the above-mentioned monocytes; and, the step of determining the infection level of the above-mentioned infectious microorganisms in the above-mentioned monocytes or dendritic cells. Alternatively, the control infection level can also be obtained from a control test conducted in advance or separately. Preferably, the two levels compared are the levels obtained by experiments conducted under the same conditions. When the infection level measured in the presence of the test drug is lower than the infection level measured in the absence of the test drug, the test drug is determined to have a therapeutic effect on the infectious disease.
[0110] <Method for producing mutant strains>
[0111] In another embodiment, the present invention relates to a method for producing a monocyte- or dendritic cell-mediated infectious microbial variant, comprising:
[0112] A step of infecting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells induced to differentiate from the monocytes, with the infectious microorganisms described above;
[0113] A step of culturing the infected monocytes or the above-mentioned dendritic cells to proliferate the above-mentioned infectious microorganisms;
[0114] A step of isolating the above-mentioned variant strain from the above-mentioned proliferated infectious microorganism.
[0115] It is known that microorganisms are introduced into a certain probability of mutation by proliferation. Since the present invention can effectively proliferate infectious microorganisms mediated by monocytes or dendritic cells in vitro in an environment close to that in vivo, it is possible to make the mutations occurring in vivo similarly introduced in vitro. Cultivation can be carried out at any time until a variant is produced, and new cells and / or culture medium can be infected as needed during the cultivation process. The separation of variants can be carried out by separating the infected microorganisms and determining their sequences. That is, it is possible to infect a cell line (for example, Vero cell line and BHK cell, etc.) known to be infected by the microorganism by appropriately diluting the solution containing the microorganism after culturing at any time, forming a single plaque, and separating the microorganism. The formation of a single plaque can be carried out by the same method as the above-mentioned plaque formation method. The genes of the separated microorganisms are analyzed, and compared with the gene sequence of the original microorganisms during infection, when the gene sequence of the original microorganisms is different from the gene sequence of the separated microorganisms, the separated microorganisms can be identified as variants. The analysis of the gene sequence can be carried out using a commercially available DNA sequencer and a next generation sequencer (NGS).
[0116] The mutant strains are not particularly limited, and examples thereof include mutant strains that can be used as live vaccines with reduced pathogenicity and drug-resistant mutant strains.
[0117] <Vaccine Manufacturing Method>
[0118] In another embodiment, the present invention relates to a method for producing a monocyte- or dendritic cell-mediated vaccine against infectious microorganisms, comprising:
[0119] A step of infecting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated and induced from the monocytes, with the infectious microorganisms described above;
[0120] A step of culturing the infected monocytes or the above-mentioned dendritic cells to proliferate the above-mentioned infectious microorganisms;
[0121] A step of recovering the above-mentioned proliferated infectious microorganisms.
[0122] The above-mentioned proliferated infectious microorganisms can be recovered from the culture supernatant or from the lysate after cell disruption. The recovered microorganisms can be used after appropriate purification as needed. The purification method can use density gradient centrifugation, ultrafiltration, affinity chromatography, etc. When the microorganism is a strain with weakened pathogenicity, the obtained microorganism can be used directly as a live vaccine. Alternatively, the above-mentioned microorganism can be used as an inactivated vaccine (including toxoid). When used as an inactivated vaccine, the method of the present invention may also include the step of lysing the recovered infectious microorganisms; and the step of recovering the antigenic part from the lysate as needed; or, the step of extracting toxins from the above-mentioned infectious microorganisms and inactivating them.
[0123] In addition, the present invention includes a vaccine produced by the above method. Further, the present invention also includes: a method for preventing the above microbial infection, comprising the step of administering the vaccine to a subject that may be infected with a monocyte- or dendritic-cell-mediated infectious microorganism; and, a method for treating the above microbial infectious disease, comprising the step of administering the vaccine to a subject that is infected with a monocyte- or dendritic-cell-mediated infectious microorganism. The manufacturing method and administration method of the vaccine preparation can be appropriately performed using methods known in the art.
[0124] <Methods for isolating infectious microorganisms>
[0125] In another embodiment, the present invention relates to a method for isolating infectious microorganisms from the blood of a patient with an infectious disease mediated by monocytes or dendritic cells, comprising:
[0126] A step of contacting monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced, or dendritic cells differentiated and induced from the monocytes, with blood from the patient;
[0127] Steps for culturing infected cells;
[0128] The step of identifying infectious microorganisms by detecting and / or identifying the microorganisms in cultured cells.
[0129] Infection and culture can be performed according to the above methods. Detection and / or identification of microorganisms in cultured cells can be performed by methods widely known in the art, such as PCR and antibodies, depending on the target microorganism.
[0130] Throughout the present specification, monocytes or dendritic cells are mammalian monocytes or dendritic cells, preferably human monocytes or human dendritic cells.
[0131] Example
[0132] Hereinafter, the present invention will be described in more detail based on examples, but the present invention is not limited to the following examples. In addition, all documents cited in the entire application are directly incorporated into the present application by reference. In addition, the dengue virus, infection test medium and dengue virus used in this example are as follows.
[0133] (Dengue virus)
[0134] Four serotypes of dengue virus were used for infection evaluation. The strains used were Mochizuki strain (dengue type 1 virus), NGC strain (dengue type 2 virus), H87 strain (dengue type 3 virus), and H241 strain (dengue type 4 virus), all of which were prototype strains. Based on a known method, each virus used the supernatant released from the culture fluid of infected Vero cells.
[0135] (Culture medium for infection experiments)
[0136] As the evaluation medium, a medium prepared by adding sodium bicarbonate (final concentration 0.225%), 100 units / ml penicillin, and 100 μg / ml streptomycin to RPM1640 medium (SIGMA) containing hypoxanthine and HEPES (SIGMA) was used.
[0137] (Example 1) Preparation of immortalized monocytes (CD14-ML) derived from human peripheral blood and preparation of dendritic cells (Preparation of immortalized monocytes derived from human peripheral blood)
[0138] Human peripheral blood-derived immortalized monocytes were prepared with reference to previously reported (WO2012 / 043651 and Japanese Patent Application Laid-Open No. 2017-131136). Specifically, CD14-positive fractions were taken from human peripheral blood, and genes reported as mouse immortalized hematopoietic stem cells (Myc, Myb, Hob8, TLX1, E2A-pbx1, MLL, Ljx2, RARA, Hoxa9, Notch1, v-raf / v-myc, MYST3-NCOA2, Evi1, HOXB6, HOSB4, β-catenin, Id1) or genes reported for human immortalized monocytes were introduced to prepare the immortalized monocytes. Immortalized monocytes were cultured in α-MEM medium containing 20% FBS, 50ng / ml M-CSF, and 50ng / ml GM-CSF. Proliferative cells were obtained 4 to 5 weeks after the start of culture and stored under liquid nitrogen using a commercially available cell preservation solution.
[0139] (Confirmation of Prepared Cells)
[0140] To confirm that the prepared cells are monocyte-like cells, before infection evaluation, color evaluation, surface marker determination, morphological observation by Giemsa staining, etc. are performed by concentration. The evaluation of color by concentration is measured by visually observing the cell color when the cells are recovered with a centrifuge tube. Surface marker determination is performed using the flow cytometer CyFlowspace of Sysmex using CD11 antibody and CD14 antibody (both Biolegend). In addition, regarding staining, Giemsa staining or MayGiemsa staining according to a known staining method is performed using a commercially available staining solution (Sigma), and measured by a high-power microscope (400 to 1000 times).
[0141] (Preparation of dendritic cells from immortalized monocytes)
[0142] The preserved immortalized monocyte cell line was maintained and prepared in α-MEM medium (containing 20% FBS, 50ng / ml M-CSF and 50ng / ml GM-CSF) in an incubator at 37°C and 5% CO2, and the medium was replaced every 3 days. The immortalized monocytes were cultured for 3 days in the presence of 50ng / ml M-CSF, 50ng / ml GM-CSF and 20ng / ml IL-4 to differentiate into dendritic cells to prepare dendritic cells for cell evaluation.
[0143] Figure 1The results of confirming the properties of human monocyte-like cells prepared by the method of Example 1 are shown in Figure 2. This result shows that the obtained human monocyte-like cells are cells expressing surface markers (CD11 and CD14) specific to monocytic lineage cells. Since the expression levels of various CD14s are mixed, it is shown that not only classical monocytes but also intermediate monocytes and non-classical monocytic lineage cells are included.
[0144] Figure 2 2 shows a Giemsa staining image of the human monocyte-like cell population of Example 1. The Giemsa staining image shows protrusions in the shape of the cell membrane, indicating that the cells include cells undergoing dendritic cell transformation due to local physical stimulation or the like.
[0145] (Example 2) Preparation of immortalized monocytes (iPS-ML) derived from human induced pluripotent stem cells
[0146] Human immortalized monocytes derived from human induced pluripotent stem (iPS) cells were prepared with reference to the already reported (WO2012 / 043651 and Japanese Patent Publication No. 2017-131136). In detail, undifferentiated iPS cells were inoculated after applying Matrigel such as laminin-511 as a basement membrane in advance, and differentiation induction culture was started using α-MEM medium (containing 20% FBS). After that, the α-MEM medium (containing 20% FBS) was replaced once every 3 days and culture continued. 18 days after the start of differentiation induction, the cells were treated with trypsin-EDTA (ethylenediaminetetraacetic acid)-collagenase solution (37°C, 60 minutes) to lyse and recover them, and a cell suspension was prepared by pipetting. Next, the cells from one 10 cm diameter culture dish were suspended in 10 ml of DMEM (containing 10% FBS) medium and seeded in two 10 cm diameter culture dishes without feeder cells and gelatin coating. After 3 hours, the cells not attached to the culture dishes were collected and passed through a 100 μm mesh (cell filter manufactured by BD Falcon) to obtain a cell suspension from which cell aggregates were removed.
[0147] The cell suspension obtained above was suspended and cultured in α-MEM medium (containing 20% FBS, 50ng / ml M-CSF and 100ng / ml GM-CSF). After that, after about 3 to 9 days, suspended or weakly attached cells appeared, and the number of cells was observed to gradually increase. The suspended cells (iPS-MC) were recovered, and the expression of leukocyte marker molecule CD45 and myeloid cell marker CD11b or CD33 was confirmed using flow cytometry.
[0148] The above-obtained suspension cells (iPS-MC) were introduced with genes (Myc, Myb, Hob8, TLX1, E2A-pbx1, MLL, Ljx2, RARA, Hoxa9, Notch1, v-raf / v-myc, MYST3-NCOA2, Evi1, HOXB6, HOSB4, β-catenin, Id1) as mouse immortalized hematopoietic stem cell reporter or genes in human immortalized monocyte reporter to produce immortalized monocytes derived from human induced pluripotent stem cells. The immortalized monocyte cell line was cultured in an α-MEM medium containing 20% FBS, 50ng / ml M-CSF and 50ng / ml GM-CSF, and proliferative cells were obtained 4 to 5 weeks after the start of culture, and stored under liquid nitrogen using a commercially available cell preservation solution.
[0149] (Example 3) Filtration and purification of prepared human immortalized monocyte-like cells
[0150] The physical properties of the two cells are evaluated when the prepared human peripheral blood-derived immortalized monocytes (CD14-ML) and human pluripotent stem cell-derived immortalized cells (iPS-ML) are supplied as products. That is, when the product is supplied, a large number of cells need to be cultured for the evaluation of about 10 million to 100 million cells at a time in infectious disease research. In order to ensure the reproducibility of the evaluation, it is hoped that the error between batches will be controlled to a minimum. In terms of this quantity control, it is estimated that physical filtration purification has advantages over flow cytometry and the like in terms of cost and operating time. Therefore, after the prepared human immortalized monocyte-like cell group is recovered, it is suspended in the culture medium and passed through a mesh filter (12μm, manufactured by Murata Manufacturing Co., Ltd.) pre-soaked with a liquid. The cell group that has passed is recovered and centrifuged to unify it to a certain cell size.
[0151] Figure 7As the physical properties of the human immortalized monocyte-like cell population prepared by the methods of Example 1 and Example 2, the measurement results using a flow cytometer after filtration purification are shown. It shows that the human peripheral blood-derived monocytes (CD14-ML) prepared by Example 1 can be purified by filtration purification, etc. On the other hand, it is shown that although the immortalized monocytes (iPS-ML) derived from human induced pluripotent stem (iPS) cells can be generated at a certain size after the cells are filtered by the measurement filter, the cell death rate is increased due to cell cutting, etc. This shows that the immortalized monocyte-like cells (CD14-ML) derived from human peripheral blood have a stronger cell membrane or stronger stress tolerance than the immortalized monocyte-like cells (iPS-ML) derived from human pluripotent stem cells.
[0152] (Example 4) Transfer of prepared human monocyte-like cells
[0153] The human monocyte and dendritic cell population preparation equipment and infection evaluation equipment are preferably in the same equipment, but sometimes it is necessary to transfer. When transferring the prepared cell population to the infection evaluation equipment, transfer it under the following conditions. Before starting the transfer, 1×10 of each of the human immortalized monocytes or dendritic cells prepared according to the description of Example 1 and Example 2 were added to the 1×10 7 Transfer about 100 cells to a T-25 culture flask with a low adsorption coating and fill it with culture medium. Wrap the container in a biobag in a sealed state, and then put it into TACPack (a constant temperature transport package that can maintain a certain temperature for a long time, manufactured by Tamai Chemical) for transfer. The cells are transferred at around 36°C using the constant temperature agent in the box. In addition, when the filter cap is not sealed and used, an anaerobic gas generating bag (AnaeroPack, manufactured by Mitsubishi Gas Chemical Co., Ltd.) is sealed in the biobag to control the O2 and CO2 concentrations for transfer. The transfer time is about 24 hours. After transfer (about 24 hours later), the cell survival rate was over 70%, and no changes in the cell status were confirmed.
[0154] (Example 5) Dengue virus infection test using immortalized monocytes (CD14-ML) and dendritic cells derived from human peripheral blood
[0155] After arriving at the transfer site, human peripheral blood-derived immortalized monocytes (CD14-ML) or dendritic cells were quickly detached using trypsin and transferred from the T-25 culture flask to a centrifuge tube, and the recovered cells were used for evaluation. If not used immediately, transfer to a 100 mm culture dish, etc., and replace the culture medium every 3 days.
[0156] according to Figure 3 The plate design shown in the figure is based on a final cell count of 1 × 10 5 Immortalized human peripheral blood mononuclear cells (CD14-ML) (1×10 7) were seeded onto a 96-well plate. The dendritic cell wells were filled with α-MEM medium containing IL-4 (containing 20% FBS, 50ng / ml M-CSF, 50ng / ml GM-CSF, and 20ng / ml IL-4), and the monocyte wells were filled with α-MEM medium not containing IL-4 (containing 20% FBS, 50ng / ml M-CSF, and 50ng / ml GM-CSF), and cultured in an incubator at 37°C and 5% CO2 for 3 days. The obtained cells were used for evaluation.
[0157] according to Figure 3 The plate design shown in the figure was used to incubate the dengue virus of each serotype in a 96-well plate with immortalized human peripheral blood-derived monocytes (CD14-ML) or dendritic cells (1×10 5 / well) were mixed for infection and cultured in an evaluation medium at 37°C and 5% CO2. After 72 hours, the culture supernatant was recovered and the infection titer of the progeny virus contained in the supernatant was measured by plaque assay. Specifically, the virus dilution was inoculated into Vero cells, adsorbed at 37°C for 1 hour, and then cultured at 37°C for 3 days in MEM supplemented with 1% methylcellulose. The cultured cells were fixed with acetone / methanol and immunostained. Immunostaining was performed according to a known method, using a mouse-derived flavivirus cross monoclonal antibody (D1-4G2-4-15 (ATCC (registered trademark) HB-112)) as the primary antibody (room temperature for 30 minutes), and reacted with a biotin-labeled anti-mouse IgG antibody (room temperature for 30 minutes), avidin-biotin complex (room temperature for 30 minutes), and a VIP substrate (room temperature for 30 minutes) in the secondary antibody in sequence. The number of infected cells that became immunopositive was measured under a microscope to calculate the virus titer.
[0158] In addition, infected human peripheral blood-derived immortalized mononuclear cells (CD14-ML) cultured for 72 hours were fixed with acetone / methanol and immunostained. Immunostaining was performed according to a known method, using a mouse-derived flavivirus cross monoclonal antibody (D1-4G2-4-15 (ATCC (registered trademark) HB-112)) as a primary antibody (room temperature for 30 minutes), and reacting with a biotin-labeled anti-mouse IgG antibody (room temperature for 30 minutes), avidin-biotin complex (room temperature for 30 minutes), and VIP substrate (room temperature for 30 minutes) in sequence among the secondary antibodies. Immunopositive infected cells were observed and evaluated under a microscope.
[0159] Figure 4The cells in each well after staining are shown in the figure. If virus infection is confirmed, the staining is darker, and it is determined that human dendritic cells (columns 1 to 6: white arrows) are well stained even with low virus concentrations compared to the positive control (columns 7 to 12: black arrows). Therefore, it is shown that dendritic cells induced from monocytes with proliferation ability prepared by the method described in Example 1 are infected with dengue virus. It can be considered that by adding candidate drugs under such experimental conditions, the ability to inhibit dengue virus infection can be evaluated. Figure 5 As shown in (A), for dengue virus type 1, stronger infection was confirmed in monocyte-like cells (A1) compared with the control (A7) sensitized with the same concentration of virus, and this result shows that it is more suitable for quantitative evaluation of drugs.
[0160] Figure 6 The amount of virus released by dengue virus sensitization is shown. It can be seen that the amount of virus released by dendritic cells is greater than that of the positive control K562 cells, so it is suitable for virus growth and acquisition of mutants using cells that are closer to humans.
[0161] (Example 6) Dengue virus infection test 2 using human monocyte-like cells and dendritic cells
[0162] After human peripheral blood-derived immortalized monocytes (CD14-ML) and human pluripotent stem cell-derived immortalized monocytes (iPS-ML) arrive at the transfer site, they are quickly detached using trypsin or the like and transferred from the T-25 culture flask to a centrifuge tube. After recovery, they are transferred to a 100 mm culture dish or the like, and the culture medium is replaced every 3 days.
[0163] according to Figure 8 The plate design shown is based on a final cell count of 1 × 10 5 Human monocyte-like cells (1×10 7 When the morphology of monocyte-like cells was directly evaluated, α-MEM medium (20% FBS, 50 ng / ml M-CSF, 50 ng / ml GM-CSF) was used, and when the morphology of dendritic cells was evaluated, α-MEM medium containing IL-4 (containing 20% FBS, 50 ng / ml M-CSF, 50 ng / ml GM-CSF and 20 ng / ml IL-4) was used, and cultured in an incubator at 37°C and 5% CO2 for 3 days. The cells obtained after 3 days were used for evaluation.
[0164] according to Figure 8 The plate design shown in the figure is to inoculate dengue virus of various serotypes at adjusted MOI concentrations with human dendritic cells (1×10 5The cells were mixed with 100 μg / well of the culture medium for infection and cultured in an evaluation medium at 37°C and 5% CO2. The supernatant was recovered after 72 hours, and the infectious titer of the progeny virus contained in the supernatant was measured by plaque assay. Fig. 9 The plate design shown in Figure 1 is based on the dilution ratio of the inoculation Figure 8 The supernatant of each well (which is believed to be released due to virus proliferation) was added to Vero cells, adsorbed at 37°C for 1 hour, and then cultured at 37°C for 3 days in MEM supplemented with 1% methylcellulose. The cultured cells were fixed with acetone / methanol and immunostained. Immunostaining was performed according to a known method, using a mouse-derived flavivirus cross monoclonal antibody (D1-4G2-4-15 (ATCC (registered trademark) HB-112)) as the primary antibody (room temperature for 30 minutes), and reacted with the biotin-labeled anti-mouse IgG antibody in the secondary antibody (room temperature for 30 minutes), avidin-biotin complex (room temperature for 30 minutes), and VIP substrate (room temperature for 30 minutes).
[0165] Fig.10 The results of plaque assays of dendritic cells (CD14-DC) derived from human peripheral blood and dendritic cells (iPS-DC) derived from human induced pluripotent stem (iPS) cells using dengue virus type 4 (DENV-4) are shown in the figure. Dengue virus invades human dendritic cells and proliferates, releasing progeny viruses, and the supernatant during recovery contains the released progeny viruses. For this reason, secondary culture was performed on Vero cells and then stained. It can be seen that compared with the virus detection limits of commonly used K562 cells and Vero cells, dendritic cells (CD14-DC) derived from human peripheral blood and dendritic cells (iPS-DC) derived from human induced pluripotent stem (iPS) cells can proliferate and detect viruses even at extremely low concentrations (concentrations of white arrows and black arrows. The sensitivity is more than 100 times that of existing cells, and can be more than 1000 times depending on the type of virus). This indicates that by evaluating under such experimental conditions, viruses can be detected and separated with high sensitivity, and even other viruses such as flaviviruses that were previously difficult to culture due to low virus concentrations can be cultured in an environment that enables evaluation of drugs.
[0166] Fig.11The results of a plaque assay using dendritic cells (CD14-DC) derived from human peripheral blood using dengue virus type 1 (DENV-1) are shown in the figure. The formation of plaques reflects the state of the virus. Small spots (white arrows) and large spots (black arrows) were confirmed in this experiment. The results show changes in the state of the virus, indicating that viral mutations can occur with just one infection test. This indicates that a new research and development method (method for constructing, developing and producing vaccine strains) can be provided for the problem that mutations were previously difficult to cause and the construction, development and production of vaccine candidate strains required a long time.
Claims
1. A method for maintaining dendritic cell-mediated dengue virus culture, comprising: A step of infecting the dengue virus with dendritic cells differentiated from monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced; and Steps for culturing infected cells; The dengue virus is dengue virus type 1 or dengue virus type 4.
2. A method for maintaining dendritic cell-mediated dengue virus culture, comprising: A step of introducing at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene into monocytes; A step of inducing differentiation of dendritic cells from any of the monocytes; a step of infecting the obtained dendritic cells with the dengue virus; and Steps for culturing infected cells; The dengue virus is dengue virus type 1 or dengue virus type 4.
3. A method for identifying a dendritic cell-mediated dengue virus infectious disease therapeutic drug, comprising: In the presence of a test drug, the dengue virus is infected with dendritic cells induced by differentiation from monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene are introduced; as well as, A step of determining the infection level of the dengue virus in the dendritic cells; The step of determining whether the drug under test has the therapeutic effect of the infectious disease according to the infection status of the dengue virus obtained by the determination; The infection level of the dengue virus obtained by the determination is compared with the infection level of a control in which the dengue virus is infected in the cells in the absence of the test drug. If the former is lower, it is determined that the test drug has the therapeutic effect of the infectious disease; The dengue virus is dengue virus type 1 or dengue virus type 4.
4. A method for preparing a dendritic cell-mediated dengue virus variant, comprising: A step of infecting the dengue virus with dendritic cells differentiated from monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced; and The step of culturing the infected dendritic cells to proliferate the dengue virus; A step of isolating a mutant strain from the propagated dengue virus; The dengue virus is dengue virus type 1 or dengue virus type 4.
5. A method for producing a dendritic cell-mediated dengue virus vaccine, comprising: A step of infecting the dengue virus with dendritic cells differentiated from monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced; The step of culturing the infected dendritic cells to proliferate the dengue virus; A step of recovering the proliferated dengue virus; The dengue virus is dengue virus type 1 or dengue virus type 4.
6. The method according to claim 5, wherein: The method also includes a step of inactivating the recovered dengue virus.
7. A method for isolating dengue virus from the blood of a patient with an infectious disease mediated by dendritic cells, comprising: a step of contacting dendritic cells induced to differentiate from monocytes into which at least one gene selected from the group consisting of BMI1 gene, EZH2 gene, MDM2 gene, MDM4 gene, HIF1A gene, BCL2 gene and LYL1 gene and cMYC gene have been introduced with blood from the patient; Steps for culturing infected cells; The step of identifying dengue virus by detecting and / or identifying the microorganism in cultured cells; The dengue virus is dengue virus type 1 or dengue virus type 4.
8. The method according to any one of claims 1 to 7, wherein: The monocytes are cells obtained by inducing differentiation of human pluripotent stem cells or human hematopoietic stem cells, or cells separated from human peripheral blood.
9. The method according to claim 8, wherein: The human pluripotent stem cells are iPS cells.
10. The method according to any one of claims 1 to 7, wherein: The method further includes a step of preparing monocytes by inducing differentiation of human pluripotent stem cells or human hematopoietic stem cells, or a step of preparing monocytes by separation from human peripheral blood.
11. The method according to claim 10, wherein: The human pluripotent stem cells are iPS cells.
12. The method according to any one of claims 1, 2, 4-7, wherein: The culture time is 24 to 96 hours.
13. The method according to claim 4, wherein: The number of cultivations ranged from 1 to 5 times.
